GLP-1 Medications and Eye Strokes: What You Need to Know About NAION (Updated March 2026)

Dr. Matthew Pham, OD  |  Eye Eye Doc  |  Katy, TX

March 15, 2026

If you're on Ozempic, Wegovy, or Mounjaro, you may’ve seen the headlines linking these drugs to a rare eye condition. The condition is called NAION (non-arteritic anterior ischemic optic neuropathy), and it's essentially a stroke of the optic nerve. It causes sudden, painless vision loss, usually in one eye, often noticed when waking up.

Here's what the research actually says, what your real risk factors are, and what you can do about it.

What is NAION?

NAION is the most common acute optic neuropathy in adults over 50. Blood flow to the front part of the optic nerve gets cut off, causing sudden vision loss. Think of it like a stroke, but for your optic nerve instead of your brain.

It's estimated to affect 2.3-10.2 cases per 100,000 people per year. It's rare, and the vision loss from NAION is serious and typically permanent. There's no well-established treatment once it happens. That's why prevention and risk awareness are very important.

The GLP-1 Connection: What the Studies Show

A review study suggests a possible dosage link of GLP-1 with onset of NAION. Wegovy and Ozempic are identical GLP-1 blockers with the only thing being different is dosage strength. While both have demonstrated cases of NAION, the higher dose Wegovy has shown more relative cases. GLP-1 may be causing fluid shifts and vascular tone laxity in the optic nerve which would cause a lack of blood flow to the optic nerve inducing an eye stroke.

The initial alarm: A 2024 study from Massachusetts General Brigham (published in JAMA Ophthalmology) found that patients prescribed semaglutide were 4x more likely to develop NAION if diabetic, and over 7x more likely if using it for weight loss.

The bigger picture: Since then, larger studies have come in with mixed results. A massive analysis across 14 databases covering 66 million patients found no significant increase in NAION risk. A meta-analysis of 69 randomized controlled trials also showed no statistically significant association.

But it's not all reassuring: A Danish-Norwegian cohort study of 424,152 people with type 2 diabetes found semaglutide roughly doubled the 5-year NAION risk compared to SGLT-2 inhibitors. An FDA adverse event analysis found 96 reported NAION cases, with 83 (86.5%) attributed to semaglutide specifically. The median time to onset was about 186 days (roughly 6 months).

The European Medicines Agency (EMA) now lists NAION as a "very rare" side effect of semaglutide, potentially affecting up to 1 in 10,000 users. The WHO issued a safety alert in June 2025 recommending the Risk Management Plan for semaglutide include NAION as a potential risk.

Dosage Matters: Ozempic vs. Wegovy

Here's a detail that matters: Ozempic (used for diabetes) maxes out at 2mg per week. Wegovy (used for weight loss) goes up to 2.4mg per week. They're the same molecule, semaglutide, just different doses.

The pattern in the data is that higher GLP-1 exposure correlates with more reported NAION cases. That correlates with the proposed mechanism: more GLP-1 activity could mean more fluid shifts and vascular changes around the optic nerve.

Why Mounjaro May Be Different

For patients that have higher risk for eye complications, Mounjaro with its dual GLP-1 and GIP shows lower incidents of NAION. It's believed that GIP dampens the GLP-1 response and may even lower NAION risk with its ability to separately improve sleep apnea.

The largest global analysis to date (over 30 million adverse event reports) found no increased risk of NAION with tirzepatide. That's a meaningful difference from the semaglutide data.

Why might this be? Tirzepatide works on 2 receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Researchers believe the GIP component may buffer the vascular effects of GLP-1 on the optic nerve. GIP receptors also have demonstrated neuroprotective properties in preclinical studies.

There's another angle too. Sleep apnea is one of the strongest risk factors for NAION (relative risk of 3.28x). The SURMOUNT-OSA trial showed tirzepatide reduced sleep apnea severity by about 22 events per hour. If Mounjaro is treating sleep apnea better than pure GLP-1 drugs, that could be independently lowering NAION risk.

NAION Risk Factors and Possible Causes

The table below maps out the major risk factors for NAION, the strength of evidence, and what to watch for.

Risk Factor	Association	Proposed Mechanism	Key Evidence	Clinical Note
Semaglutide (Ozempic/Wegovy)	Moderate to Strong (debated)	Fluid shifts and vascular tone laxity reducing optic nerve blood flow	HR 2.81 (Danish cohort); 86.5% of FDA-reported GLP-1 NAION cases	Higher doses (Wegovy 2.4mg) show more cases than lower doses (Ozempic 2mg)
Tirzepatide (Mounjaro/Zepbound)	Low (no significant signal)	Dual GIP/GLP-1 action; GIP may buffer vascular effects	No increased risk in 30M+ report analysis	May reduce NAION risk via sleep apnea improvement
PDE5 Inhibitors (Viagra, Cialis)	Possible (FDA classification)	Vasodilation and blood pressure drops affecting optic nerve perfusion	~2.8 cases per 100,000 patient-years; contraindicated after first NAION event	Highest concern when combined with other NAION risk factors
Diabetes Mellitus	Moderate (RR = 1.53)	Microvascular damage to small vessels supplying the optic nerve	24-26% of NAION patients are diabetic	Good blood sugar control is protective
Hypertension	Moderate (RR = 1.28)	Chronic vascular damage; nocturnal blood pressure drops reduce optic nerve perfusion	47-49% of NAION patients have hypertension	Monitor nocturnal BP; avoid over-treating at night
Obstructive Sleep Apnea	Strong (RR = 3.28)	Repeated oxygen drops and increased intracranial pressure during sleep	Highest relative risk among systemic factors; NAION often occurs upon waking	Get screened and treated; CPAP is protective
High Cholesterol	Moderate (RR = 1.43)	Atherosclerotic changes in small vessels	Consistently identified in meta-analyses	Statin therapy may help reduce vascular risk
Small Optic Disc ("Disc at Risk")	Strong (anatomic)	Crowded nerve fibers create a compartment syndrome when swelling occurs	Cup-to-disc ratio ≤0.3 found in 62% of NAION patients	Can be identified on a routine eye exam

What You Can Do

For patients who are concerned about eye stroke risks, they should consider the least amount of GLP-1 dosing. That would either be not using a GLP-1, using Mounjaro (tirzepatide), or the lowest effective dose of Ozempic over Wegovy. By lowering the amount of GLP-1 effects, then a decreased risk of NAION is expected. Which is important because there isn't really a good treatment option should a NAION attack happen.

1. Talk to your prescribing doctor about dosing. If you're on semaglutide primarily for weight management and you have other NAION risk factors, discuss whether a lower dose or switching to tirzepatide makes sense.

2. Control your systemic health. Keep diabetes, blood pressure, and cholesterol well managed. These are independent NAION risk factors, and stacking them with GLP-1 use increases your overall risk.

3. Watch for drug interactions. If you're taking PDE5 inhibitors (Viagra, Cialis, Levitra) for erectile dysfunction, know that these already carry a known NAION risk. Combining them with semaglutide means you're stacking 2 potential risk factors. Talk to your doctor.

4. Get screened for sleep apnea. Sleep apnea carries the highest relative risk for NAION among systemic factors (3.28x). If you snore heavily, wake up tired, or have been told you stop breathing at night, get a sleep study. CPAP treatment is protective.

5. Get an eye exam. An eye exam can evaluate your optic nerve size and health. Patients with a small, crowded optic disc ("disc at risk") are more vulnerable to NAION. This is something we check during a comprehensive exam. We can also rule out other causes of optic nerve problems, like glaucoma.

The Bottom Line

The evidence on GLP-1 drugs and NAION is still evolving. The risk appears to be real but rare, likely dose-dependent, and concentrated in patients who already have other vascular risk factors. Semaglutide (especially at higher Wegovy doses) has the most concerning signal. Tirzepatide (Mounjaro) looks safer for the eyes based on current data.

The best thing you can do? Know your risk factors, keep your systemic health in check, and get your eyes examined regularly. If you notice any sudden vision changes while on these medications, contact your eye doctor immediately.

Disclaimer: This post is for educational purposes and is not medical advice. Always consult your prescribing physician and eye care provider about your specific situation. If you experience sudden vision loss, seek care immediately.

Sources

Hathaway et al., 2024. JAMA Ophthalmology. Risk of NAION in Patients Prescribed Semaglutide.

Cai et al., 2025. JAMA Ophthalmology. Semaglutide and NAION across 14 databases (66M patients).

Silverii, 2025. Diabetes Obesity & Metabolism. Meta-analysis of 69 RCTs.

Simonsen et al., 2025. Danish-Norwegian Cohort Study. HR 2.81 for semaglutide vs. SGLT-2i.

European Medicines Agency (EMA), 2025. PRAC conclusion on semaglutide and NAION.

World Health Organization (WHO), June 2025. Safety alert on semaglutide and NAION.

Frontiers in Medicine, 2021. Large-scale meta-analysis of NAION risk factors.

PMC, 2022. PDE5 Inhibitors and NAION: Literature Review.

SURMOUNT-OSA Trial. Tirzepatide and obstructive sleep apnea outcomes.